ERNA PE Ratio & Valuation, Is ERNA Overvalued

Historical Valuation

Ernexa Therapeutics Inc (ERNA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.18. The fair price of Ernexa Therapeutics Inc (ERNA) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.27

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Ernexa Therapeutics Inc (ERNA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Ernexa Therapeutics Inc (ERNA) has a current Price-to-Book (P/B) ratio of 2.55. Compared to its 3-year average P/B ratio of 1.42, the current P/B ratio is approximately 80.26% higher. Relative to its 5-year average P/B ratio of -5.53, the current P/B ratio is about -146.10% higher. Ernexa Therapeutics Inc (ERNA) has a Forward Free Cash Flow (FCF) yield of approximately -103.64%. Compared to its 3-year average FCF yield of -162.37%, the current FCF yield is approximately -36.17% lower. Relative to its 5-year average FCF yield of -118.23%, the current FCF yield is about -12.34% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ERNA competitors is 4.27, providing a benchmark for relative valuation. Ernexa Therapeutics Inc Corp (ERNA.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ERNA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ERNA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ERNA currently overvalued or undervalued?

What is Ernexa Therapeutics Inc (ERNA) fair value?

ERNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Ernexa Therapeutics Inc (ERNA) is between to according to relative valuation method.

How does ERNA's valuation metrics compare to the industry average?

The average P/S ratio for ERNA's competitors is 4.27, providing a benchmark for relative valuation. Ernexa Therapeutics Inc Corp (ERNA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Ernexa Therapeutics Inc (ERNA) as of Mar 20 2026?

As of Mar 20 2026, Ernexa Therapeutics Inc (ERNA) has a P/B ratio of 2.55. This indicates that the market values ERNA at 2.55 times its book value.

What is the current FCF Yield for Ernexa Therapeutics Inc (ERNA) as of Mar 20 2026?

As of Mar 20 2026, Ernexa Therapeutics Inc (ERNA) has a FCF Yield of -103.64%. This means that for every dollar of Ernexa Therapeutics Inc's market capitalization, the company generates -103.64 cents in free cash flow.

What is the current Forward P/E ratio for Ernexa Therapeutics Inc (ERNA) as of Mar 20 2026?

As of Mar 20 2026, Ernexa Therapeutics Inc (ERNA) has a Forward P/E ratio of -0.01. This means the market is willing to pay $-0.01 for every dollar of Ernexa Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ernexa Therapeutics Inc (ERNA) as of Mar 20 2026?

As of Mar 20 2026, Ernexa Therapeutics Inc (ERNA) has a Forward P/S ratio of 0.00. This means the market is valuing ERNA at $0.00 for every dollar of expected revenue over the next 12 months.

ERNA Valuation